Development of extramedullary sites of leukaemia during ruxolitinib therapy for myelofibrosis. uri icon

Overview

publication date

  • May 26, 2014

Research

keywords

  • Antineoplastic Agents
  • Neoplasms, Second Primary
  • Primary Myelofibrosis
  • Protein Kinase Inhibitors
  • Pyrazoles
  • Sarcoma, Myeloid

Identity

Scopus Document Identifier

  • 84908887878

Digital Object Identifier (DOI)

  • 10.1111/bjh.12948

PubMed ID

  • 24862179

Additional Document Info

volume

  • 167

issue

  • 1